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Introduction {#jdi12742-sec-0005}
============

Diabetes mellitus has been an epidemic worldwide, the number of patients with diabetes mellitus all over the world is estimated to reach 642 million by 2040[1](#jdi12742-bib-0001){ref-type="ref"}. Patients with type 1 diabetes mellitus rely on exogenous insulin whether through continuous subcutaneous insulin infusion or multiple daily insulin injections to help control their blood glucose level. In addition, more and more individuals with type 2 diabetes mellitus start to use insulin because of failure of oral hypoglycemic medications and recommendations from updated guidelines[2](#jdi12742-bib-0002){ref-type="ref"}. Lipohypertrophy (LH) is a common complication of insulin therapy. It has been reported that patients with LH have an almost sixfold higher occurrence of unexplained hypoglycemia compared with patients without LH, and sevenfold higher occurrence of glycemic variability[3](#jdi12742-bib-0003){ref-type="ref"}. Suboptimal glycemic control also increases the risk of cardiovascular disease[4](#jdi12742-bib-0004){ref-type="ref"}, amputation[5](#jdi12742-bib-0005){ref-type="ref"}, retinal diseases[6](#jdi12742-bib-0006){ref-type="ref"}, kidney disease[7](#jdi12742-bib-0007){ref-type="ref"} and a range of other diseases, as diabetes mellitus can affect multiple organs. Furthermore, LH can increase economic burden, as diabetes patients with LH consume more insulin[8](#jdi12742-bib-0008){ref-type="ref"}. As a consequence, it is crucial to discern LH from normal skin in diabetes patients through credible methods during their usual follow‐up visits, and give them some advice from professionals\' perspective. However, present epidemiological data showed that the prevalence of LH in people with diabetes mellitus ranged widely from 1.9% to 73.4% in different studies[9](#jdi12742-bib-0009){ref-type="ref"}, [10](#jdi12742-bib-0010){ref-type="ref"}. Various factors accounted for this vast difference, including study quality, not using the LH detection gold standard and the detection capacity of diverse screening staff involved across studies. In order to inform efforts to prevent, treat and identify influencing factors of LH among diabetes patients, dependable estimates of LH prevalence are required. To our knowledge, no systematic review and meta‐analysis has been found that quantified the prevalence of LH in patients with diabetes mellitus. The present systematic review, therefore, set out to establish pooled prevalence levels of LH among patients with diabetes mellitus, and to investigate the impacts of study variables on prevalence estimates.

Methods {#jdi12742-sec-0006}
=======

Literature search {#jdi12742-sec-0007}
-----------------

We searched four electronic data repositories (PubMed, EMBASE, The Cochrane Library and Scopus), and the main search terms were: "diabetes," "diabetes mellitus," "lipohypertrophy," "insulin lipohypertrophy," "subcutaneous induration," "endermic induration" and "subcutaneous nodules." The detailed search strategy is shown in Appendix [S1](#jdi12742-sup-0001){ref-type="supplementary-material"}. The search was limited to papers written in English published from the above databases\' inception to April 2017. We also screened the reference lists of retrieved publications, and consulted experts in the field with the purpose of identifying relevant publications reporting the prevalence of LH among diabetes patients.

Study selection {#jdi12742-sec-0008}
---------------

Two authors independently searched four electronic databases, and browsed titles and read abstracts to decide whether the full text should be examined according to the established inclusion and exclusion criteria. Disagreement was resolved by discussing with a third party. Agreement between reviewers in relation to study relevancy was assessed using Cohen\'s kappa. We included articles that fulfilled the following criteria: (i) cross‐sectional design, baseline cross‐sectional data from a longitudinal study or baseline cross‐sectional data from a trial, before random allocation; (ii) detected LH by careful examination (at least observation and palpation), studies involving self‐report LH prevalence by patients were also included if the sample size was more than 500; (iii) participants were insulin‐treated patients with type 1 diabetes mellitus or type 2 diabetes mellitus. We excluded the following studies: commentaries, review articles, case reports, letters to the editor, studies in languages other than English, and studies with participants who did not have diabetes or were pregnant.

Data extraction {#jdi12742-sec-0009}
---------------

Two investigators extracted the data independently using a specific extraction form. The extracted data included the name of the first author, year of study publication, country, sample size, percentage of male participants, mean age of participants, number of participants with type 1 diabetes mellitus/type 2 diabetes mellitus, mean diabetes mellitus duration, mean insulin treatment duration, reported prevalence of LH and detection methods of LH. If there were multiple papers from longitudinal or cohort studies, publications were included according to their epidemiological quality.

Quality assessment {#jdi12742-sec-0010}
------------------

We used a modified version of the Newcastle--Ottawa Scale[11](#jdi12742-bib-0011){ref-type="ref"} to assess the methodological quality of every study included in the present meta‐analysis. The total score ranges from 0 to 5, with ≥3 points indicating low risk of bias and \<3 points indicating high risk of bias. The scale assesses quality in several domains: sample representativeness and size, comparability between respondents and non‐respondents, ascertainment of LH, and statistical quality. The detailed assessment process can be seen in Appendix [S2](#jdi12742-sup-0002){ref-type="supplementary-material"}.

Statistical analysis {#jdi12742-sec-0011}
--------------------

Data analysis was carried out using the meta‐analysis software Stata version 12 (StataCorp, College Station, TX, USA). For evaluation of the pooled effect, a 95% confidence interval (CI) was considered, and statistical significance was set at a *P* \< 0.05. We used random effects to pool studies reporting the prevalence of LH in patients with diabetes mellitus. Between‐study heterogeneity was assessed by the *I* [2](#jdi12742-bib-0002){ref-type="ref"} with thresholds of ≥25%, ≥50% and ≥75% indicating low, moderate and high heterogeneity, respectively. The influence of an individual study on the overall prevalence estimate was explored by consecutively excluding each study in sensitivity analyses. Subgroup analyses were undertaken based on overall study quality, sample size, country of origin, type of diabetes mellitus and publication year, when there was more than one study in the subgroup. Funnel plots and Egger\'s test were combined to explore the potential publication bias in this meta‐analysis.

Results {#jdi12742-sec-0012}
=======

Characteristics of the participants in selected studies {#jdi12742-sec-0013}
-------------------------------------------------------

The Reporting Items for Systematic reviews and Meta‐Analysis (PRISMA) statement[12](#jdi12742-bib-0012){ref-type="ref"} was used to outline the selection process for eligible studies (Figure [1](#jdi12742-fig-0001){ref-type="fig"}). The characteristics of the included studies are presented in Table [1](#jdi12742-tbl-0001){ref-type="table-wrap"}. A total of 26 published studies matched the inclusion criteria, reporting on a total of 12,493 patients with diabetes mellitus. Interrater reliability of reviewers regarding study relevancy was high (Kappa = 0.86). Nine studies took place in Asia[8](#jdi12742-bib-0008){ref-type="ref"}, [10](#jdi12742-bib-0010){ref-type="ref"}, [13](#jdi12742-bib-0013){ref-type="ref"}, [14](#jdi12742-bib-0014){ref-type="ref"}, [15](#jdi12742-bib-0015){ref-type="ref"}, [16](#jdi12742-bib-0016){ref-type="ref"}, [17](#jdi12742-bib-0017){ref-type="ref"}, [18](#jdi12742-bib-0018){ref-type="ref"}, [19](#jdi12742-bib-0019){ref-type="ref"}, 14 in Europe[2](#jdi12742-bib-0002){ref-type="ref"}, [3](#jdi12742-bib-0003){ref-type="ref"}, [9](#jdi12742-bib-0009){ref-type="ref"}, [20](#jdi12742-bib-0020){ref-type="ref"}, [21](#jdi12742-bib-0021){ref-type="ref"}, [22](#jdi12742-bib-0022){ref-type="ref"}, [23](#jdi12742-bib-0023){ref-type="ref"}, and one each in North America[31](#jdi12742-bib-0031){ref-type="ref"}, Africa[32](#jdi12742-bib-0032){ref-type="ref"} and a mix of different countries[33](#jdi12742-bib-0033){ref-type="ref"}. The median of the mean ages was 46 years (range 6.5--63.8 years), and the median percentage of males represented in the sample was 50% (range 27.3--59.1%). In addition, the median number of participants per study was 228 (range 54--4352), the median of mean disease duration was 10.0 years (range 2.8--17.0 years) and the median of mean insulin treatment duration was 9.3 years (range 3.0--15.0 years). When evaluated by the modified Newcastle--Ottawa quality assessment criteria, out of 5 possible points, one study received 5 points[24](#jdi12742-bib-0024){ref-type="ref"}, seven studies received 4 points[3](#jdi12742-bib-0003){ref-type="ref"}, [10](#jdi12742-bib-0010){ref-type="ref"}, [15](#jdi12742-bib-0015){ref-type="ref"}, [18](#jdi12742-bib-0018){ref-type="ref"}, [26](#jdi12742-bib-0026){ref-type="ref"}, [28](#jdi12742-bib-0028){ref-type="ref"}, [29](#jdi12742-bib-0029){ref-type="ref"}, 14 received 3 points[2](#jdi12742-bib-0002){ref-type="ref"}, [9](#jdi12742-bib-0009){ref-type="ref"}, [14](#jdi12742-bib-0014){ref-type="ref"}, [16](#jdi12742-bib-0016){ref-type="ref"}, [17](#jdi12742-bib-0017){ref-type="ref"}, [19](#jdi12742-bib-0019){ref-type="ref"}, [20](#jdi12742-bib-0020){ref-type="ref"}, [21](#jdi12742-bib-0021){ref-type="ref"}, [22](#jdi12742-bib-0022){ref-type="ref"}, [24](#jdi12742-bib-0024){ref-type="ref"}, [27](#jdi12742-bib-0027){ref-type="ref"}, [30](#jdi12742-bib-0030){ref-type="ref"}, [31](#jdi12742-bib-0031){ref-type="ref"}, [33](#jdi12742-bib-0033){ref-type="ref"}, three received 2 points[13](#jdi12742-bib-0013){ref-type="ref"}, [30](#jdi12742-bib-0030){ref-type="ref"}, [32](#jdi12742-bib-0032){ref-type="ref"} and one received 1 point[25](#jdi12742-bib-0025){ref-type="ref"}.

![Flowchart of literature research. LH, lipohypertrophy.](JDI-9-536-g001){#jdi12742-fig-0001}

###### 

Overview of prevalence studies of lipohypertrophy in patients with diabetes mellitus

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study ID          Country                                                           Sample size   Male (%)   Age, years (mean ± SD)   No. T1DM/T2DM   DM duration, years (mean ± SD)   Insulin treatment duration (years)   Prevalence of LH (%)   Methods for detection of LH                                 MNOS
  ----------------- ----------------------------------------------------------------- ------------- ---------- ------------------------ --------------- -------------------------------- ------------------------------------ ---------------------- ----------------------------------------------------------- ------
  McNally 1988      UK                                                                281           53.7       Mean: 45.0\              NS              NS                               Mean: 11.0                           27.1                   OAP by physicians                                           3
                                                                                                               Range: 7.0--86.0                                                                                                                                                                                  

  Hauner 1996       Germany                                                           279           44.1       40.2 ± 18.1              223/56          14.1 ± 9.5                       ≥2.0                                 23.7                   OAP by a trained physician                                  3

  Ibarra 1998       Spain                                                             150           38.0       36.9 ± 17.9              113/37          13.3 ± 8.8                       11.4 ± 7.9                           52.0                   OAP by a trained diabetes nurse                             2

  Partanen 2000     Finland                                                           100           44.0       32.0 ± 19.0              100/0           11.0 ± 9.0                       NS                                   29.0                   OAP by a diabetes specialist nurse                          3

  Raile 2001        Germany                                                           112           NS         Mean: 10.9\              112/0           Mean: 4.6\                       NS                                   43.8                   OAP by two investigators                                    1
                                                                                                               Range: 1.1--19.1                         Range: 0--15.3                                                                                                                                           

  Strauss 2002      Seven European countries[†](#jdi12742-note-0003){ref-type="fn"}   1002          49.2       46.9 ± 18.4              581/421         14.7 ± 10.6                      ≥0.5                                 27.0                   OAP by trained diabetes nurses                              4

  Pavlovic 2007     Serbia                                                            212           53.3       12.5 ± 3.7               212/0           4.2 ± 3.0                        NS                                   1.9                    OAP by two experienced dermatologists                       3

  Vardar 2007       Turkey                                                            215           36.3       Mean: 59.6               31/184          NS                               ≥2.0                                 48.8                   Observation and palpation techniques                        4

  Schober 2009      Austria                                                           78            52.6       6.5 ± 4.9                78/0            NS                               NS                                   46.2                   OAP by researchers                                          3

  Coninck 2010      Sixteen countries[‡](#jdi12742-note-0003){ref-type="fn"}          4352          49.4       48.4±20.1                NS              13.9 ± 10.6                      Mean: 11.0                           47.9                   Self‐report by patients                                     4

  Hajheydari 2011   Iran                                                              220           27.3       49.0 ± 17.9              56/164          14 ± 8.5                         5.4 ± 6.0                            14.5                   OAP by one specialist physician                             3

  Cunningham 2013   Ireland                                                           55            43.6       55.2 ± 16.6              41/14           NS                               15.0 ± 12.6                          51.0                   Observation and palpation techniques                        3

  Blanco 2013       Spain                                                             430           52.2       49.0 ± 22.8              177/253         6.0--15.0                        1.0--5.0                             64.4                   Ultrasound examined, OAP by a diabetes nurse                4

  Sawatkar 2014     India                                                             500           54.4       16.9 ± 6.9               500/0           4.4 ± 4.4                        NS                                   41.0                   OAP by one dermatologist                                    3

  Ji 2014           China                                                             380           50.0       54.6 ± 8.7               0/380           NS                               3.6 ± 4.1                            35.3                   OAP by trained diabetes nurses                              4

  Grassi 2014       Italy                                                             346           51.9       55.5 ± 18.6              NS              NS                               13.0 ± 9.8                           48.7                   OAP by trained nurses                                       4

  Munster 2014      Netherlands                                                       231           50.2       14.0 ± 7.0               231/0           6.0 ± 8.0                        NS                                   34.8                   OAP by experienced pediatric diabetes nurse practitioners   4

  Binder 2015       Austria                                                           54            51.9       Median: 9.6\             54/0            Median: 3.9\                     NS                                   20.0                   OAP by medical staff                                        3
                                                                                                               Range: 7.1--13.8                         Range: 2.6--6.2                                                                                                                                          

  Berard 2015       Canada                                                            503           52.9       53.3 ± 19.7              125/378         14.7 ± 10.0                      ≥0.5                                 24.6                   Self‐report by patients                                     4

  Ajlouni 2015      Jordan                                                            1090          47.2       57.1 ± 10.3              0/1090          Median: 13.5\                    4.6 ± 5.0                            37.3                   OAP by inspection and palpation                             3
                                                                                                                                                        Range: 9.0--20.0                                                                                                                                         

  Li 2016           China                                                             736           44.7       63.8 ± 8.8               0/736           10.0 ± 6.9                       \>1.0                                73.4                   OAP by trained diabetes nurses and nursing postgraduates    4

  Hayek 2016        Saudi Arabia                                                      174           51.7       15.4 ± 2.0               174/0           6.1 ± 4.5                        \>1.0                                52.3                   OAP by a trained diabetes educator                          2

  Youssef 2016      Egypt                                                             152           48.7       8.4 ± 3.8                152/0           2.8 ± 2.9                        NS                                   23.7                   OAP by the dermatology team                                 2

  Patil 2016        India                                                             225           59.1       Mean: 50.0               30/195          Median: 6.0                      Mean: 3.0                            11.1                   OAP by investigators                                        3

  Ji 2017           China                                                             401           50.0       59.6 ± 11.5              26/375          11.8 ± 7.3                       5.8 ± 4.5                            53.1                   OAP by trained study stuff                                  5

  Hernar 2017       Norway                                                            215           51.6       Median: 36.0\            215/0           Median: 17.0\                    \>1.0                                47.4                   OAP by trained diabetes specialist nurses                   3
                                                                                                               Range: 18.0--82.0                        Range: 1.0--57.0                                                                                                                                         
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^†^Seven European countries: Sweden, Belgium, Germany, France, Italy, Spain and the UK; ^‡^16 countries: USA, Russia, the Netherlands, Belgium, France, Spain, Italy, Switzerland, the UK and Ireland, Denmark, Sweden, Germany, China, Turkey, Portugal, and Finland. DM, diabetes mellitus; LH, lipohypertrophy; MNOS, Modified Newcastle Ottawa Scale; NS, not stated; OAP, observed and palpated; SD, standard deviation; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus.

John Wiley & Sons, Ltd

Sensitivity and subgroup analyses {#jdi12742-sec-0014}
---------------------------------

Sensitivity analyses showed that the exclusion of studies with less sample representativeness (46%, 95% CI 36--55%), and fewer comparable respondents and non‐respondents \[39%, 95% CI 25%--53%) tended to increase the prevalence of LH. The sensitivity analyses through omitting studies one‐by‐one showed no abnormalities, and the result can be seen in Appendix [S3](#jdi12742-sup-0003){ref-type="supplementary-material"}. The subgroup analyses were carried out according to sample size, overall quality, publication year, country of origin and type of diabetes mellitus. Table [2](#jdi12742-tbl-0002){ref-type="table-wrap"} suggests LH prevalence estimates according to subgroup analysis. The results showed that studies with sample sizes \<200 had higher LH estimates (40%, 95% CI 30--49% *vs* 37%, 95% CI 26--47%). When evaluated by Newcastle--Ottawa criteria, studies with lower total overall quality scores yielded higher LH estimates (43%, 95% CI 28--57% *vs* 37%, 95% CI 27--46%). In contrast with clinical interviews, more recent publications tended to yield higher LH prevalence estimates. The subgroup analyses for country of origin showed that LH prevalence among Asians tended to be higher than Europeans (41%, 95% CI 27--55% *vs* 37%, 95% CI 25--49%). The subgroup analyses for diabetes mellitus type showed that LH prevalence among patients with type 2 diabetes mellitus (49%, 95% CI 23--74%) tended to be higher than type 1 diabetes mellitus (34%, 95% CI 19--49%) and a mixed type of diabetes mellitus (37%, 95% CI 25--48%; Figure [2](#jdi12742-fig-0002){ref-type="fig"}).

###### 

Impact of study characteristics on prevalence estimates for lipohypertrophy in diabetes mellitus patients: Subgroup analyses

  Subgroup analysis          *n*   95% CI              *I* ^2^ (%)   *P*‐value
  -------------------------- ----- ------------------- ------------- ----------------------------------------------
  Sample size                                                        
  \<200                      8     0.40 (0.30--0.49)   89.1          0.000[a](#jdi12742-note-0004){ref-type="fn"}
  ≥200                       18    0.37 (0.26--0.47)   99.4          0.000[a](#jdi12742-note-0004){ref-type="fn"}
  Overall quality                                                    
  \<3 points (low quality)   4     0.43 (0.28--0.57)   92.8          0.000[a](#jdi12742-note-0004){ref-type="fn"}
  ≥3 points (high quality)   22    0.37 (0.27--0.46)   99.2          0.000[a](#jdi12742-note-0004){ref-type="fn"}
  Publication year                                                   
  1990s                      3     0.34 (0.19--0.48)   94.5          0.000[a](#jdi12742-note-0004){ref-type="fn"}
  2000s                      6     0.32 (0.16--0.49)   98.9          0.000[a](#jdi12742-note-0004){ref-type="fn"}
  2010--                     17    0.40 (0.32--0.48)   98.5          0.000[a](#jdi12742-note-0004){ref-type="fn"}
  Country of origin                                                  
  Europe                     14    0.37 (0.25--0.49)   98.8          0.000[a](#jdi12742-note-0004){ref-type="fn"}
  Asia                       9     0.41 (0.27,0.55)    99.0          0.000[a](#jdi12742-note-0004){ref-type="fn"}
  Africa                     1     --                                
  North America              1     --                                
  Mixed                      1     --                                
  DM type                                                            
  T1DM                       10    0.34 (0.19--0.49)   98.6          0.000[a](#jdi12742-note-0004){ref-type="fn"}
  T2DM                       3     0.49 (0.23--0.74)   99.4          0.000[a](#jdi12742-note-0004){ref-type="fn"}
  T1DM and T2DM              10    0.37 (0.25--0.48)   98.3          0.000[a](#jdi12742-note-0004){ref-type="fn"}
  NS                         3     0.41 (0.29--0.54)   96.6          0.000[a](#jdi12742-note-0004){ref-type="fn"}

*P* \< 0.001. *I* ^2^ ≥25% (low), ≥50% (moderate), ≥75% (high). CI, confidence interval; DM, diabetes mellitus; LH, lipohypertrophy; NS, not stated; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus.

John Wiley & Sons, Ltd

![Forest plot of subgroup analysis by type of diabetes mellitus. T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus.](JDI-9-536-g002){#jdi12742-fig-0002}

Assessment of publication bias {#jdi12742-sec-0015}
------------------------------

Assessment of publication bias showed no publication bias, according to the Egger\'s test (Egger: bias = 2.35, 95% CI --5.93--10.62, *P* = 0.56) and the funnel plot (Figure [3](#jdi12742-fig-0003){ref-type="fig"}).

![Funnel plot of the meta‐analysis. SE, standard error.](JDI-9-536-g003){#jdi12742-fig-0003}

Discussion {#jdi12742-sec-0016}
==========

The present systematic review and meta‐analysis of 26 studies involved 12,493 patients with diabetes mellitus. Different studies had roughly the same definition of LH, namely, visible and palpable fatty swellings of subcutaneous adipose tissue at insulin injection or infusion sites[8](#jdi12742-bib-0008){ref-type="ref"}. The gold standard for detecting of LH is skin ultrasound scans[34](#jdi12742-bib-0034){ref-type="ref"}. The value of ultrasound examination can be seen in the case of a study carried out by Volkova *et al*.[35](#jdi12742-bib-0035){ref-type="ref"}, which showed that just eight of 50 participants had clinically evident LH, but 33 of the remaining showed ultrasound evidence of LH.

However, instead of detecting LH using ultrasound examination, most studies detected LH by observing and palpating the injection sites of patients using insulin. Up to now, there is no unified method of visual inspection and palpation. Just three[8](#jdi12742-bib-0008){ref-type="ref"}, [10](#jdi12742-bib-0010){ref-type="ref"}, [20](#jdi12742-bib-0020){ref-type="ref"} of the included studies described the methods further, and the methods referred to by Ji *et al*.[8](#jdi12742-bib-0008){ref-type="ref"} are more preferable. They took into consideration the body positions of patients when they evaluated the injection sites. For abdominal examinations, patients lay supine; for the thigh, they sat with knees bent and feet on the floor; for buttock, patients stood; and for arms, patients could sit or stand. The concrete method was that examiners washed their hands and kept them warm, then they daubed ultrasound gel on their hands and the injection sites, and the patients were then examined in a specific position by trained staff in a warm environment to avoid shivering, with oblique lighting to assist visual inspection. Light‐to‐moderate pressure with small sweeps of the fingertips was used to detect LH.

The reason why the researchers prefer observation and palpation is that it is expensive and time‐consuming to investigate LH by ultrasound scans just for the purpose of screening[3](#jdi12742-bib-0003){ref-type="ref"}. In addition, carrying out biopsies for histopathological examination to detect LH is a reliable method[36](#jdi12742-bib-0036){ref-type="ref"}, and it can avoid the misdiagnosis of amyloid lumps as LH, because they are hard to distinguish from each other by physical examination, but it is not practical or economical. Sandro *et al*.[34](#jdi12742-bib-0034){ref-type="ref"} reported a suitable palpation technique to identify LH, which reached a 97% consistency rate as compared with the gold standard. Future studies can take advantage of this approach to detect LH in a cost‐effective way. At present, patients are not competent to identify LH by themselves, so we discarded studies involving this condition unless the samples were large[31](#jdi12742-bib-0031){ref-type="ref"}, [33](#jdi12742-bib-0033){ref-type="ref"}. Furthermore, not all studies mentioned that trained medical professionals were responsible for the detection of LH, which gave implications for future studies, as non‐professionals are likely to overestimate or underestimate the prevalence of LH. We found that the prevalence of LH ranged from 1.9% to 73.4%, and the overall prevalence was 38% (95% CI 29--46%).

Subgroup analysis revealed some interesting findings. The present study found that the prevalence of LH among Asians tended to be higher than among Europeans. This inconsistency might have something to do with social and cultural elements. However, we also found that most studies carried out in Asia were published later, which was in line with the outcome that recent publications were associated with increased LH prevalence among diabetes mellitus patients. In addition, the result of subgroup analysis by type of diabetes mellitus showed that patients with type 2 diabetes mellitus were more likely to develop LH than patients with type 1 diabetes mellitus. Among studies dealing with a mixed type of diabetes mellitus, some of them[2](#jdi12742-bib-0002){ref-type="ref"}, [16](#jdi12742-bib-0016){ref-type="ref"}, [26](#jdi12742-bib-0026){ref-type="ref"}, [30](#jdi12742-bib-0030){ref-type="ref"} showed that participants with type 1 diabetes mellitus developed LH more easily, though other studies failed to come to such a conclusion[3](#jdi12742-bib-0003){ref-type="ref"}, [8](#jdi12742-bib-0008){ref-type="ref"}. This discrepancy might be due to the number of patients with different types of diabetes mellitus in those articles being unbalanced. Typically, one study[8](#jdi12742-bib-0008){ref-type="ref"} had a total sample of 401 participants, but there were just 26 patients living with type 1 diabetes mellitus, the rest of the sample were all patients with type 2 diabetes mellitus. Although studies varied widely in terms of quality, our sensitivity analyses suggested that LH prevalence estimates were reasonably stable. Furthermore, studies with lower total overall quality scores yielded higher LH estimates. The present study also showed that studies with sample size \<200 had higher LH estimates.

Because LH is associated with erratic glucose control[3](#jdi12742-bib-0003){ref-type="ref"}, [10](#jdi12742-bib-0010){ref-type="ref"}, increased risk of chronic complications[4](#jdi12742-bib-0004){ref-type="ref"}, [5](#jdi12742-bib-0005){ref-type="ref"}, [6](#jdi12742-bib-0006){ref-type="ref"}, [7](#jdi12742-bib-0007){ref-type="ref"} and increased economic burden[3](#jdi12742-bib-0003){ref-type="ref"}, [8](#jdi12742-bib-0008){ref-type="ref"}, these findings stressed that it is vital that diabetes nurses recognize this condition by inspecting and palpating insulin injecting sites regularly, and draw up a plan for patients to avoid the development of LH. Not only does LH have an influence on disease management, but it can also affect the appearance of a person. Furthermore, there is no established therapeutic method for LH, and people with severe LH must have these parts of the body removed by surgery[37](#jdi12742-bib-0037){ref-type="ref"}, therefore it is important that we discover these sites early so as to let them disappear slowly when the degree of LH is not that serious.

The present review had several limitations. First, the heterogeneity of both total population and subgroup was high, part of which could not be explained. Unexamined factors, such as age, sex, diabetes mellitus duration, insulin treatment duration and methods for detecting of LH might also contribute to the risk for LH, but we could not analyze these factors because of incomplete data. Second, the studies searched were restricted to articles published in English. Third, most studies did not use gold standard for detecting of LH, so there might be significant interobserver variation in the reporting of this condition.
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